Under one in 10 people that would benefit from obesity jabs such as Wegovy have access to them, warns the World Health Organization as it releases its first guidance on the therapies.
Given more than one billion individuals worldwide currently obese, it is calling for more widespread and fairer access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a chronic disease that can be managed with comprehensive and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to widespread access to the jabs that can aid individuals in losing considerable weight, says the body.
Skinny Jab Shortage
Even under the present most optimistic outlook, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of those who need them, as stated by the WHO.
The advice encourages governments and firms to increase access, via approaches such as licensing agreements.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
The Way Weight-Loss Drugs Work
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and increase the sense of being full so people reduce food intake.
People commonly begin shedding pounds in the initial weeks of commencing the regular doses.
Research indicates patients may see weight return within a year of discontinuing the treatment, when their typical hunger return.
To be overweight or obese elevates your likelihood for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.
